Compare Medpace Holdings Inc (MEDP) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs New York Times Co — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while New York Times Co trades at $66.32 (market cap $10.74B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and New York Times Co pays a 1.38% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and New York Times Co for 81 Days on average.
| MEDP | NYT | |
|---|---|---|
Market Cap | $16.82B | $10.74B |
Volume | 223,093 | 2,096,352 |
Sector | Health | Media |
52-Week High | $630.19 | $85.86 |
52-Week Low | $393.42 | $54.66 |
Typical Hold Time | 14 Days | 81 Days |
Enterprise Value | $16.44B | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
The New York Times Company (NYT) trades at $66.60, up 2.62% today, reflecting strong momentum after three consecutive quarterly earnings beats. Revenue and net income have grown steadily from 2022 to 2025, with profit margins expanding to 12.17%. The stock shows a bullish technical signal overall, supported by positive cash flow trends and a declared quarterly dividend of $0.23 per share. However, a recent shareholder lawsuit alleging reporting bias introduces reputational risk.
Outlook remains positive given consistent earnings outperformance and a consensus price target of $84.00, implying significant upside. Key risks include the ongoing lawsuit, competitive pressures in digital media, and potential volatility from the AI copyright dispute with OpenAI. The company's solid fundamentals and analyst support suggest resilience, but investors should weigh legal and market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
